(Q43039590)

English

Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis

scientific article published on 9 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis (English)

1 reference

Europe PubMed Central

12 November 2017

liver cirrhosis

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

12 November 2017

author name string

Sosuke Hayaishi

1

1 reference

Europe PubMed Central

12 November 2017

Hobyung Chung

2

1 reference

Europe PubMed Central

12 November 2017

Emi Ishikawa

4

1 reference

Europe PubMed Central

12 November 2017

Masahiro Takita

5

1 reference

Europe PubMed Central

12 November 2017

Taisuke Ueda

6

1 reference

Europe PubMed Central

12 November 2017

Satoshi Kitai

7

1 reference

Europe PubMed Central

12 November 2017

Tatsuo Inoue

8

1 reference

Europe PubMed Central

12 November 2017

Norihisa Yada

9

1 reference

Europe PubMed Central

12 November 2017

Satoru Hagiwara

10

1 reference

Europe PubMed Central

12 November 2017

Yasunori Minami

11

1 reference

Europe PubMed Central

12 November 2017

Kazuomi Ueshima

12

1 reference

Europe PubMed Central

12 November 2017

publication date

9 August 2011

1 reference

Europe PubMed Central

12 November 2017

Digestive Diseases

1 reference

Europe PubMed Central

12 November 2017

29

1 reference

Europe PubMed Central

12 November 2017

3

1 reference

Europe PubMed Central

12 November 2017

326-332

1 reference

Europe PubMed Central

12 November 2017

Branched-chain amino acids as a protein- and energy-source in liver cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Energy and protein requirements of patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Epidemiology of hepatocellular carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Direct effect of branched-chain amino acids on the growth and metabolism of cultured human hepatocellular carcinoma cells.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Isoleucine, an essential amino acid, prevents liver metastases of colon cancer by antiangiogenesis.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Effects of branched-chain amino acids-enriched nutrient support for patients undergoing liver resection for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Three targets of branched-chain amino acid supplementation in the treatment of liver disease

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Significance of branched chain amino acids as possible stimulators of hepatocyte growth factor

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucose-sensing apparatus in the liver.

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Hepatitis C virus infection: molecular pathways to metabolic syndrome

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?

1 reference

https://api.crossref.org/works/10.1159%2F000327571

21 January 2018

Identifiers

10.1159/000327571

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43039590&oldid=1978309621"